All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Periosteal Chondrosarcoma | NCIT_C7357 | [A chondrosarcoma arising from the surface of bone. It is characterized by a lobulated growth pattern, high mitotic activity, myxoid stroma formation, and necrotic changes. It occurs in adults. Clinical presentation includes pain, and sometimes swelling.] |
| Bone Sarcoma | NCIT_C9312 | [A sarcoma that arises from the bone. Representative examples are osteosarcoma and chondrosarcoma.] |
| Chondrosarcoma | NCIT_C2946 | [A malignant cartilaginous matrix-producing mesenchymal neoplasm arising from the bone and soft tissue. It usually affects middle-aged to elderly adults. The pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.] |
| Grade 5 Hypoparathyroidism, CTCAE | NCIT_C146361 | [Death] |
| Hypoparathyroidism, CTCAE | NCIT_C143572 | [A disorder characterized by a decrease in production of parathyroid hormone by the parathyroid glands.] |
| Juxtacortical Chondrosarcoma | NCIT_C7358 | |
| Agent Affecting Digestive System or Metabolism | NCIT_C78276 | [An agent that exerts an effect on metabolism or any anatomic entity that is part of the gastrointestinal tract.] |
| Histamine-2 Receptor Antagonist | NCIT_C29702 | [Any agent that competitively binds to and blocks the histamine H2 receptors found in the stomach, heart, uterus, on vascular smooth muscle and in the central nervous system (CNS). Of particular clinical relevance is the blockage of H2 receptors found on the parietal cells of the stomach, which prevents gastric acid secretion.] |
| Antilipidemic Agent | NCIT_C29703 | [An agent that reduces plasma lipids, such as cholesterol or low density lipoproteins (LDL), acting systemically or locally (intestines) to decrease fat digestion, absorption, production, and accumulation in the plasma and reducing pathogenic atherosclerosis and thrombosis.] |
| Grade 5 Hypophosphatemia, CTCAE | NCIT_C146362 | [Death] |
| Hypophosphatemia, CTCAE | NCIT_C143573 | [A disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood.] |
| Grade II Squamous Intraepithelial Neoplasia | NCIT_C7351 | |
| Grade II Intraepithelial Neoplasia | NCIT_C8368 | |
| High Grade Squamous Intraepithelial Neoplasia | NCIT_C8336 | [A precancerous neoplastic process characterized by the presence of moderate or severe dysplastic cytological changes which extend to the upper part of the squamous epithelium. Maturation at the surface of the squamous epithelium may or may not be present. Representative examples include the high grade esophageal squamous intraepithelial neoplasia, high grade cervical squamous intraepithelial neoplasia, high grade vaginal intraepithelial neoplasia, and high grade vulvar intraepithelial neoplasia.] |
| Grade 5 Hypophysitis, CTCAE | NCIT_C146363 | [Death] |
| Hypophysitis, CTCAE | NCIT_C143193 | [A disorder characterized by inflammation and cellular infiltration of the pituitary gland.] |
| Retroperitoneal Carcinoma | NCIT_C7352 | [A rare carcinoma that arises from the retroperitoneal space.] |
| Malignant Retroperitoneal Neoplasm | NCIT_C3537 | [A primary or metastatic malignant neoplasm involving the retroperitoneum. The vast majority of cases are carcinomas, lymphomas, or sarcomas.] |
| Grade 5 Hypopituitarism, CTCAE | NCIT_C146364 | [Death] |
| Hypopituitarism, CTCAE | NCIT_C143194 | [A disorder characterized by a decrease in production of hormones from the pituitary gland.] |